Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Merck & Co., Inc. Director's Dealing 2019

Jan 10, 2019

284_dirs_2019-01-10_eaeb2064-6ecb-4a42-baf5-451f6ac3e116.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2019-01-01

Reporting Person: Clyburn Frank (EVP, Chief Commercial Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 61724.9410 Direct
Common Stock - 401(k) Plan 1395.4461 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Phantom Stock $ Common Stock (2059.8360) Direct
Restricted Stock Unit $ 2021-05-04 Common Stock (5714.0000) Direct
Restricted Stock Unit $ 2020-05-05 Common Stock (3752.0000) Direct
Restricted Stock Unit $ 2019-05-10 Common Stock (4389.0000) Direct
Restricted Stock Unit $ 2021-10-30 Common Stock (6862.0000) Direct
Stock Option (right to buy) $39.2900 2022-05-01 Common Stock (43876.0000) Direct
Stock Option (right to buy) $44.9800 2023-05-05 Common Stock (38647.0000) Direct
Stock Option (right to buy) $54.6800 2026-05-09 Common Stock (54329.0000) Direct
Stock Option (right to buy) $57.7500 2028-05-03 Common Stock (40255.0000) Direct
Stock Option (right to buy) $58.2200 2024-05-01 Common Stock (38514.0000) Direct
Stock Option (right to buy) $58.3300 2025-02-08 Common Stock (5500.0000) Direct
Stock Option (right to buy) $59.8600 2025-04-30 Common Stock (43344.0000) Direct
Stock Option (right to buy) $63.9700 2027-05-04 Common Stock (34237.0000) Direct

Footnotes

F1: Holdings include shares acquired in dividend reinvestment transactions.

F2: Includes shares acquired and dividends earned through January 1, 2019, in the Merck U.S. Savings Plan, a 401(k) plan.

F3: The Merck & Co., Inc. Deferral Program includes the right of redesignation to other investement measures within the Program.

F4: Distributions of phantom stock are made in shares of Common Stock of Merck & Co., Inc., with cash payable for partial shares, in accordance with a distribution schedule elected by the reporting person. This distribution is subject to conditions and limitations of the Merck & Co., Inc. Deferral Program.

F5: 1-for-1

F6: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.

F7: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F8: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.

F9: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.

F10: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.

F11: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

F12: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.

F13: The option became exercisable in equal installments on 5/2/2015, 5/2/2016 and 5/2/2017.

F14: The option became exercisable in equal installments on 2/9/2016, 2/9/2017 and 2/9/2018.

F15: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.

F16: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.